Moderna’s Flu Flop & Alnylam’s Enzymatic Empire: A Tale of Two RNAs
Beyond the headlines—why a "Refusal-to-File" signals a regulatory crackdown on mRNA shortcuts, while RNAi quietly solves the manufacturing bottleneck.
The Signal:
Two massive stories dropped in the last 24 hours that define the current state of the industry. Moderna (MRNA) received a stinging “Refusal-to-File” letter from the FDA for its seasonal flu vaccine (mRNA-1010), effectively stalling its post-COVID pivot. Meanwhile, Alnylam (ALNY) announced a $250 million expansion of its Norton, MA facility to deploy “siRELIS,” a proprietary enzymatic ligation platform that promises to revolutionize how we manufacture oligonucleotides at scale.[1][2]
RapidGene Take:
The FDA is done grading on a curve. During the pandemic, speed was the only metric that mattered. Moderna’s RTF letter—citing an inadequate “comparator” in their clinical design—is a brutal return to standard operating procedure. They tried to game the trial design to look better against a standard-dose flu shot rather than the enhanced vaccines (like Fluzone High-Dose) that actually dominate the elderly market. It’s a rookie regulatory mistake for a company of this size. Contrast this with Alnylam: while Moderna fights over clinical trial design, Alnylam is solving the hardest problem in the room—chemical manufacturing costs. Moving from chemical synthesis to enzymatic ligation is the “Henry Ford moment” for RNAi. One is playing marketing games; the other is doing process engineering. Guess who I’m betting on?
Expanded Read: The Era of “Good Enough” is Over
The market reacted to Moderna’s earnings beat, but the real story is buried in that Refusal-to-File (RTF) letter. An RTF isn’t just a rejection; it’s the FDA saying, “This is so flawed we won’t even waste our time reviewing it.”
The Moderna Misstep (Regulatory & Strategy):
Moderna’s mRNA-1010 was supposed to be the proof that mRNA can conquer the seasonal flu market. But the data has been whelming—not overwhelming. By choosing a standard-dose comparator, Moderna likely hoped to show statistical superiority. The FDA, however, knows that the standard of care for the vulnerable population (65+) is enhanced vaccines. If you can’t beat the best product on the market, you don’t get to play. This signals a massive shift: the “mRNA premium” is gone. Payers and regulators now demand superior efficacy, not just a cool delivery mechanism.
The Alnylam Advantage (CMC & Scalability):
While Moderna licks its wounds, Alnylam is quietly changing the physics of the business.
The Old Way: Solid-phase chemical synthesis. It’s dirty, requires massive amounts of acetonitrile (solvent), and scales linearly (and expensively).
The New Way (siRELIS): Enzymatic ligation.[1][2] This is biology doing chemistry. It allows for the assembly of longer, more complex RNA strands with higher purity and a fraction of the solvent waste.
The “So What?”: This isn’t just about being “green.” It’s about COGS (Cost of Goods Sold). If Alnylam can drop the manufacturing cost of siRNA by 50% using enzymes, they can price their drugs competitively for common diseases (like hypertension and heart disease) rather than just rare genetic disorders.
The Verdict:
Moderna is discovering that being a “platform company” doesn’t exempt you from basic drug development fundamentals. Alnylam, on the other hand, has turned profitable and is reinvesting in the process. In the long run, process wins.
Keywords:
Sources